(SEATTLE), December 21, 2020 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder. AGC Biologics will manufacture GMP material for the next stage of clinical trial.
Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004
by David Self Published on 12/21/20 7:00 AM News
Learn More
Follow Us
Content not found